Crohn’s Disease - Epidemiology Forecast to 2029

Crohns Disease - Epidemiology Forecast to 2029



Crohns disease (CD) is an inflammatory bowel disease (IBD) characterized by chronic inflammation of the gastrointestinal tract. It most commonly affects the end of the small intestine (the ileum) where it joins the beginning of the colon. Crohns disease may appear in patches, affecting some areas of the gastrointestinal tract while leaving other sections completely untouched. (Crohns and Colitis Foundation of America, 2014). Men and women can both be affected and the disease can occur at any age, but CD is more prevalent among women and in the young age population. Diet and stress may aggravate CD, but do not cause the disease. (Crohns and Colitis UK, 2018; Crohns and Colitis Foundation, 2020a).

epidemiologists utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed incident cases and diagnosed prevalent cases of CD in the 8MM. epidemiologists applied the incidence and prevalence of CD drawn from the above sources to each countrys population to calculate the number of estimated diagnosed incident cases and diagnosed prevalent cases for CD.

The following data describes the epidemiology of CD. In the 8MM, epidemiologists forecast an increase in the diagnosed incident cases of CD from 90,318 cases in 2019 to 95,574 cases in 2029, at an Annual Growth Rate (AGR) of 0.58%. In the 8MM, the diagnosed prevalent cases of CD are expected to increase from 1,339,543 cases in 2019 to 1,629,940 cases in 2029, at an AGR of 2.17%. In 2029, the US will have the highest number of diagnosed prevalent cases of CD in the 8MM, with 827,859 diagnosed prevalent cases, and whereas Japan will have the fewest diagnosed prevalent cases with 48,560 cases.

Scope

- The Crohns Disease Epidemiology Report provides an overview of the risk factors and global trends of Crohns Disease (CD) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and Canada).
- The report includes a 10-year epidemiology forecast for the diagnosed incident cases and diagnosed prevalent cases of CD. The diagnosed incident cases of CD are segmented by age and sex.
- The diagnosed prevalent cases of CD are segmented by age, sex, and severity (mild to moderate, moderate to severe, and severe to fulminant). The diagnosed prevalent cases of CD are further segmented by fistulizing CD based on the severity (mild to moderate, moderate to severe, and severe to fulminant).
- The CD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The CD Epidemiology series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CD markets.
- Quantify patient populations in the global CD markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CD therapeutics in each of the markets covered.
- Understand magnitude of CD population by its severity.
1
1.1
1.2
2 Crohns Disease: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Forecast Assumptions and Methods: Diagnosed Incident Cases of CD
3.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CD
3.4.5 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of CD by Severity and Diagnosed Prevalent Cases of Fistulizing CD by Severity
3.5 Epidemiological Forecast for CD (2019-2029)
3.5.1 Diagnosed Incident Cases of CD
3.5.2 Age-Specific Diagnosed Incident Cases of CD
3.5.3 Sex-Specific Diagnosed Incident Cases of CD
3.5.4 Diagnosed Prevalent Cases of CD
3.5.5 Age-Specific Diagnosed Prevalent Cases of CD
3.5.6 Sex-Specific Diagnosed Prevalent Cases of CD
3.5.7 Diagnosed Prevalent Cases of CD by Severity
3.5.8 Diagnosed Prevalent Cases of Fistulizing CD by Severity
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Coronavirus Disease 2019 (COVID-19) Impact
3.6.3 Limitations of the Analysis
3.6.4 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 Primary Research - Prescriber Survey
4.3 About the Authors
4.3.1 Epidemiologist
4.3.2 Reviewers
4.3.3 Global Director of Therapy Analysis and Epidemiology
4.3.4 Global Head and EVP of Healthcare Operations and Strategy
4.4 About GlobalData
4.5 Contact Us
4.6 Disclaimer

List Of Tables


Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for CD
Table 4: High-Prescribing Physicians (non-KOLs) Surveyed for Severity of CD, By Country
Table 5: High-Prescribing Physicians (non-KOLs) Surveyed for Severity of Fistulizing CD, By Country

List Of Figures


Figure 1: 8MM, Diagnosed Incident Cases of CD, Both Sexes, N, All Ages, 2019 and 2029
Figure 2: 8MM, Diagnosed Prevalent Cases of CD, Both Sexes, N, All Ages, 2019 and 2029
Figure 3: 8MM, Diagnosed Incidence of CD, Men and Women, Cases per 100,000 Population, All Ages, 2019
Figure 4: 8MM, Diagnosed Prevalence of CD, Men and Women, %, All Ages, 2019
Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CD
Figure 6: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CD
Figure 7: 8MM, Diagnosed Incident Cases of CD, N, Both Sexes, All Ages, 2019
Figure 8: 8MM, Diagnosed Incident Cases of CD by Age, N, Both Sexes, 2019
Figure 9: 8MM, Diagnosed Incident Cases of CD by Sex, N, All Ages, 2019
Figure 10: 8MM, Diagnosed Prevalent Cases of CD, N, Both Sexes, All Ages, 2019
Figure 11: 8MM, Diagnosed Prevalent Cases of CD by Age, N, Both Sexes, 2019
Figure 12: 8MM, Diagnosed Prevalent Cases of CD by Sex, N, All Ages, 2019
Figure 13: 8MM, Diagnosed Prevalent Cases of CD by Severity, N, All Ages, 2019
Figure 14: 8MM, Diagnosed Prevalent Cases of Fistulizing CD by Severity, N, All Ages, 2019

Global Inflammatory Bowel Disease (IBD) Market – Analysis By Disease Indication (Crohn’s Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)

Executive Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and

USD 2400 View Report

Crohn’s Disease - Global Drug Forecast and Market Analysis to 2029

Crohns Disease - Global Drug Forecast and Market Analysis to 2029Crohns disease (CD) is a form of inflammatory bowel disease (IBD), which is composed of two chronic autoimmune diseases that

USD 10995 View Report

Lyme Disease - Pipeline Insight, 2021

DelveInsights, Lyme Disease - Pipeline Insight, 2021, report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Lyme Disease pipeline landscape. It covers the pipeline drug profiles, including

USD 1500 View Report

Acute Graft-versus-Host Disease - Pipeline Insight, 2021

DelveInsights, Acute Graft-versus-Host Disease - Pipeline Insight, 2021, report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Acute Graft-versus-Host Disease pipeline landscape. It covers the pipeline drug

USD 2000 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available